Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants (BabyCOVE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05584202 |
|
Recruitment Status :
Recruiting
First Posted : October 18, 2022
Last Update Posted : May 22, 2023
|
Sponsor:
ModernaTX, Inc.
Information provided by (Responsible Party):
ModernaTX, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| SARS-CoV-2 | Biological: mRNA-1273.214 Other: Placebo | Phase 2 |
The study will be conducted in 2 parts. Part 1 will be open-label and evaluate 2 dose levels. The dose level selected from Part 1 will be further evaluated in Part 2, which will be blinded and randomized. This pediatric study is intended to confirm safety and effectiveness of mRNA-1273.214 in infants between 12 weeks to < 6 months of age by comparing the immune response of infants in this study to adults (>18 years of age) enrolled in the mRNA-1273-P301 study [NCT04470427]).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 700 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Intervention Model Description: | Part 1: sequential Part 2: parallel |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Part 1: open-label Part 2: observer-blinded, randomized, placebo-controlled |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months |
| Actual Study Start Date : | September 30, 2022 |
| Estimated Primary Completion Date : | March 8, 2024 |
| Estimated Study Completion Date : | March 8, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1: mRNA-1273.214 Dose A
Participants will receive 2 doses of mRNA-1273.214 Dose A by intramuscular (IM) injection approximately 8 weeks apart (Day 1 and Day 57).
|
Biological: mRNA-1273.214
Sterile liquid for injection |
|
Experimental: Part 1: mRNA-1273.214 Dose B
Participants will receive 2 doses of mRNA-1273.214 Dose B by IM injection approximately 8 weeks apart (Day 1 and Day 57).
|
Biological: mRNA-1273.214
Sterile liquid for injection |
|
Experimental: Part 2: mRNA-1273.214
Participants will receive 2 doses of mRNA-1273.214 by IM injection approximately 8 weeks apart (Day 1 and Day 57).
|
Biological: mRNA-1273.214
Sterile liquid for injection |
|
Placebo Comparator: Part 2: Placebo
Participants will receive 2 doses of placebo by IM injection approximately 8 weeks apart (Day 1 and Day 57).
|
Other: Placebo
0.9% sodium chloride
Other Name: normal saline |
Primary Outcome Measures :
- Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [ Time Frame: Up to Day 64 (7 days after each vaccination) ]
- Number of Participants with Unsolicited Adverse Events (AEs) [ Time Frame: Up to Day 85 (28 days after each vaccination) ]
- Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs) [ Time Frame: Up to Day 422 ]
- Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Against Omicron Variant [ Time Frame: Day 85 (28 days after the second vaccination) ]
- Seroresponse Rate Against SARS-CoV-2 Omicron Variant [ Time Frame: Day 85 (28 days after the second vaccination) ]
Secondary Outcome Measures :
- GMT of SARS-CoV-2 Antibodies Against Omicron Variant (Part 1) [ Time Frame: Day 85 (28 days after the second vaccination) ]
- GMT of SARS-CoV-2 Antibodies Against Omicron Variant (Part 2) [ Time Frame: Day 85 (28 days after the second vaccination) ]
- Seroresponse Rate Against SARS-CoV-2 Omicron Variant (Part 2) [ Time Frame: Day 85 (28 days after the second vaccination) ]
- GMT of SARS-CoV-2 Antibodies Against Original Strain (Part 2) [ Time Frame: Day 85 (28 days after the second vaccination) ]
- Seroresponse Rate Against SARS-CoV-2 Original Strain (Part 2) [ Time Frame: Day 85 (28 days after the second vaccination) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Months to 6 Months (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Key Inclusion Criteria:
-
Participant is male or female, between 2 and <6 months of age at the time of consent (Screening Visit), who is in good general health, in the opinion of the investigator, based on review of medical history and screening physical examination.
- Participant must be at least 12 weeks completed age and must not have completed 6 months at the time of administration of first dose.
- If the participant has a chronic, stable disease, they may be eligible to enroll in Part 2, but ineligible for Part 1. The chronic condition (for example, gastroesophageal reflux disease) should be stable, per investigator assessment, so that the participant can be considered eligible for inclusion in Part 2.
- Participant was born at ≥37 weeks gestation (Part 1) or ≥34 weeks gestation (Part 2), with a minimum birth weight of 2.5 kilograms (kg), without fetal growth restriction, and the participant's height and weight are both at or above the second percentile for age according to the Centers for Disease Control and Prevention/World Health Organization Child Growth Standard at the Screening Visit.
- In the investigator's opinion, the parent(s)/legally authorized representative(s) understand and are willing and physically able to comply with protocol-mandated follow-up, including all procedures, and provide written informed consent.
Key Exclusion Criteria:
- Participant has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of study drug or has a known close contact in the past 2 weeks to someone diagnosed with SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19). Participants may be rescreened after 14 days provided that they remain asymptomatic.
- Participant is acutely ill or febrile 72 hours prior to or at the Screening Visit. Fever is defined as a body temperature ≥38.0°Celcius/≥100.4°Farenheit. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
- Participant has previously been administered an investigational or approved CoV (for example, SARS-CoV-2, SARS-CoV, Middle East respiratory syndrome [MERS]-CoV) vaccine.
- Participant has undergone treatment with investigational or approved agents for prophylaxis against COVID-19 (for example, receipt of SARS-CoV-2 monoclonal antibodies) within 90 days prior to enrollment.
- Participant has a known hypersensitivity to a component of the vaccine or its excipients. Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to any of the components of messenger ribonucleic acid (mRNA) COVID-19 vaccines (including polyethylene glycol or immediate allergic reaction of any severity to polysorbate).
- Participant has a medical, psychiatric, or occupational condition, that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.
- Participant has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
-
Participant has received the following:
- Any routine vaccination with inactivated or live vaccine(s) within 14 days prior to first or second vaccination or plans to receive such a vaccine within 14 days of any study vaccination.
- Systemic immunosuppressants or immune-modifying drugs (including maternal use during pregnancy or lactation) for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥ 1 milligrams (mg)/kg/day or, if participant weighs >10 kg: ≥10 mg/day prednisone equivalent). Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids are allowed.
- Intravenous or subcutaneous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to enrollment.
- Participant has participated in an interventional clinical study within 28 days prior to the Screening Visit or plans to do so while participating in this study, or maternal participation in an interventional clinical study during pregnancy.
Note: Other inclusion and exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05584202
Contacts
| Contact: Moderna Clinical Trials Support Center | 1-877-777-7187 | clinicaltrials@modernatx.com |
Locations
Show 40 study locations
Sponsors and Collaborators
ModernaTX, Inc.
| Responsible Party: | ModernaTX, Inc. |
| ClinicalTrials.gov Identifier: | NCT05584202 |
| Other Study ID Numbers: |
mRNA-1273-P206 |
| First Posted: | October 18, 2022 Key Record Dates |
| Last Update Posted: | May 22, 2023 |
| Last Verified: | May 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by ModernaTX, Inc.:
|
mRNA-1273 mRNA-1273 vaccine mRNA-1273.214 vaccine mRNA-1273.214 SARS-CoV-2 SARS-CoV-2 Vaccine Coronavirus |
Virus Diseases Messenger RNA COVID 19 COVID 19 Vaccine Moderna Bivalent omicron vaccine Omicron vaccine |